Literature DB >> 19201565

Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR.

Vaijanath G Dongre1, Pradeep D Ghugare, Pravin Karmuse, Dharmendra Singh, Atul Jadhav, Ashok Kumar.   

Abstract

The focus of this study is identification and characterization of major unknown impurities in chloroquine (CQ) and hydroxychloroquine (HCQ) bulk drug samples using liquid chromatography/ion trap mass spectrometry (LC/IT/MS) and liquid chromatography/time of flight mass spectrometry (LC/TOF/MS). The newly developed LC/MS method was employed for the analysis of both the drugs. The analysis revealed the presence of two impurities in each of the drugs. The impurities are designated as CQ-I, CQ-II (for chloroquine); HCQ-I and HCQ-II (for hydroxychloroquine). Three of the impurities, CQ-II, HCQ-I and HCQ-II were unknown have not been reported previously. Accurate masses of the impurities were determined by using Q-TOF mass spectrometer and fragmentation behavior was studied by an ion trap mass spectrometer. Based on the spectrometric data and synthetic specifics the structures of CQ-II, HCQ-I and HCQ-II were proposed as 1,4 pentanediamine, N(4)(7-chloro-4-quinolinyl), N(4)-chloromethyl, N(4)-ethylamine; 2-(4-(7-chloroquinolin-4-ylamino) pentylamino) ethanol and [[4-[(7-chloro-4-quinolyl) amino] N-pentyl] N-chloromethyl-N-ethylamino] ethanol respectively. The impurities were isolated by semi-preparative HPLC and structures were confirmed by NMR spectroscopy. The formation and through characterization of known CQ-I impurity is also discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201565     DOI: 10.1016/j.jpba.2009.01.013

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  7 in total

1.  Stability Indicating LC Method Development for Hydroxychloroquine Sulfate Impurities as Available for Treatment of COVID-19 and Evaluation of Risk Assessment Prior to Method Validation by Quality by Design Approach.

Authors:  Thirupathi Dongala; Naresh Kumar Katari; Ashok Kumar Palakurthi; Lakshmi Narasimha Rao Katakam; Vishnu Murthy Marisetti
Journal:  Chromatographia       Date:  2020-08-25       Impact factor: 2.044

2.  Ultraviolet-coupled advanced oxidation processes for anti-COVID-19 drugs treatment: Degradation mechanisms, transformation products and toxicity evolution.

Authors:  Tenghao Huang; Junjie Guo; Gang Lu
Journal:  Chemosphere       Date:  2022-05-14       Impact factor: 8.943

3.  Identification of process related trace level impurities in the actinide decorporation agent 3,4,3-LI(1,2-HOPO): Nozzle-skimmer fragmentation via ESI LC-QTOFMS.

Authors:  Nagender R Panyala; Manuel Sturzbecher-Hoehne; Rebecca J Abergel
Journal:  J Pharm Biomed Anal       Date:  2014-08-12       Impact factor: 3.935

Review 4.  HPLC methods for choloroquine determination in biological samples and pharmaceutical products.

Authors:  Yugo Araújo Martins; Talita Mota Gonçalves; Renata F V Lopez
Journal:  Daru       Date:  2021-03-19       Impact factor: 3.117

5.  Development of an easy and rapid analytical method for the extraction and preconcentration of chloroquine phosphate from human biofluids prior to GC-MS analysis.

Authors:  Süleyman Bodur; Sezin Erarpat; Ömer Tahir Günkara; Sezgin Bakırdere
Journal:  J Pharmacol Toxicol Methods       Date:  2021-01-24       Impact factor: 1.950

6.  A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate using ultra-high-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry and liquid chromatography-solid-phase extraction-nuclear magnetic resonance.

Authors:  Donghai Xu; Fangfang Pan; Hao Ruan; Nan Sun
Journal:  Rapid Commun Mass Spectrom       Date:  2022-10-30       Impact factor: 2.586

7.  Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review.

Authors:  Immacolata Faraone; Fabiana Labanca; Maria Ponticelli; Nunziatina De Tommasi; Luigi Milella
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.